Systemic carboplatin for retinoblastoma: change in tumour size over time

D H Abramson, S D Lawrence, K L Beaverson, T C Lee, I S Rollins, I J Dunkel

Background/aim: Chemotherapy for intraocular retinoblastoma is used to shrink individual retinal tumours to a size amenable to focal treatments. Quantitative data regarding retinal tumour response following treatment with primary systemic carboplatin are reported.

Methods: Changes in area and largest basal diameter of tumours that were exposed to carboplatin, had no concomitant focal treatment, and had digital funduscopy photography performed before and after treatment, were measured. Response was evaluated.

Results: 36 tumours were measured following one treatment: 34/36 (94.4%) responded, with a 37.1% mean decrease in area (median = 37.0%; range 4.0%–76.7%). Mean reduction in basal diameter was 21.3% (med = 21.0%; −7.9%–52.5%). 20 tumours were treated with a second cycle: 15/20 (75.0%) responded. Mean decrease in area was 17.8% (med = 15.3%; −7.0%–49.7%). The mean cumulative decrease in area after two treatments was 55.1% (med = 56.2%; 33.0%–74.5%). Mean cumulative reduction in basal diameter was 33.6% (med = 33.6%; 10.9%–53.2%). 12 tumours were treated with a third cycle: 3/12 (25.0%) responded, 8/12 were stable, and one progressed. Mean decrease in area was 5.4% (med = 7.2%; −17.7%–20.6%). Cumulative decrease in area after three treatments was 58.1% (med = 57.3%; 34.8%–77.2%). Mean cumulative reduction in basal diameter was 38.8% (med = 38.2%; 19.1%–54.1%).

Conclusions: Carboplatin caused measurable shrinkage of retinoblastoma tumours. Response was greatest following the initial treatment and decreased with subsequent treatments.

P rimary chemotherapy is often used to treat intraocular retinoblastoma, but when used alone, it is rarely curative. For select eyes, chemotherapy may be used to shrink retinal tumours (chemoreduction) to a size cured by the application of focal techniques such as cryotherapy, brachytherapy, and laser photocoagulation. The protocol most commonly used to achieve chemoreduction is a combination of vincristine, etoposide, and carboplatin (VEC). Ciclosporin may be added to the regimen with the goal of decreasing multidrug resistance.1 One’s choice of drugs, dosage and treatment schedule must weigh patient/ tumour response against the risks and/or complications of treatment. Known risks of chemotherapy treatment exist; including, haematological (myelosuppression) and gastrointestinal distress and infection.2 Furthermore, eyes remain at risk for new retinal tumour development following treatment with chemotherapy.3 Known complications of chemoreduction plus focal therapies also exist; including, rhegmatogenous retinal detachment in the setting of chemoreduction plus cryotherapy,4 and focal iris atrophy, peripheral focal lens opacity, retinal traction, retinal vascular occlusion, and transient localised serous retinal detachment in the setting of chemotherapy.5 The development of additional cancers has been reported following treatment with chemotherapy. Secondary myelodysplastic syndrome/ acute myelogenous leukaemia is a rare, but devastating, side effect of a number of chemotherapeutic agents, but has been particularly associated with etoposide.6 Known patient/ tumour response data to chemoreduction techniques are most often defined by outcome variables associated with ocular and patient survival, as well as avoidance of external beam radiotherapy (EBR). The most consistent correlate for success is extent of intraocular disease; Reese-Ellsworth group (RE) I–III eyes usually avoid EBR and enucleation, while RE group IV–V eyes have lower success rates.7 Several studies have examined the effects of systemic chemotherapy on intraocular retinoblastoma in the setting of concomitant focal therapies.8–13 These studies accurately reflect common clinical practice, but when reporting outcome data, their methodology does not allow for the evaluation of any isolated effect of chemotherapy on tumour morphology.

A few studies have attempted to rigorously quantify the change in retinal tumour size following primary treatment with chemotherapy by means of serial measurements, pretreatment and post-treatment.14–16 These published studies focus on response after two and three drug regimens and measure tumour dimensions by various methods. All report notable shrinkage after a single cycle of chemotherapy, with decreased continued reduction following successive doses. We are unaware of any study to date that has quantified reduction in tumour size as a function of a single agent, systemic chemotherapy, in the absence of additional treatment(s).

PATIENTS AND METHODS
We performed a retrospective study of retinoblastomas that met the following criteria: (1) they were identified in patients diagnosed with intraocular bilateral or unilateral retinoblastoma, (2) they were exposed to primary carboplatin only, and (3) they had adequate digital fundus photographs (RET-CAM) taken before and after exposure to systemic carboplatin. Thirty-six tumours in 27 eyes of 21 patients who were diagnosed with retinoblastoma at the Memorial Sloan-Kettering Cancer Center (MSKCC) fulfilled the inclusion criteria and were analysed.

Abbreviations: CBC, complete blood count; CTT, chemothermotherapy; dd, disc diameter; EBR, external beam radiotherapy; RE, Reese-Ellsworth; TTT, transpalpebral thermotherapy; VEC, vincristine, etoposide, and carboplatin

Correspondence to:
David H Abramson, MD,
70 East 66th Street, New York, NY 10021, USA;
DHAMD@aol.com

Accepted for publication
1 August 2005
Retinal tumour changes after carboplatin

The largest basal diameter of each tumour was measured from RET-CAM images at baseline and following each cycle of systemic carboplatin. Tumours were censored from the study when treatment was performed in order to evaluate systemic effects of the drug. Ophthalmological examinations were performed at 3–4 week intervals (average).

**Statistical methods**

All statistical analyses were performed using SAS (version 8.1, Cary, NC, USA). Percentage reduction in tumour area following an initial cycle of carboplatin treatment was compared with tumour response after a second and third cycle by means of a two tailed Student’s *t* test (alpha = 0.05). Percentage reduction in tumour area (per treatment) was then considered as a function of initial size of tumour using the initial largest basal diameter (0–4 disc diameters versus >4 disc diameters, where 1 disc diameter (dd) = 1.5 mm), also using the Student’s *t* test (alpha = 0.05). Finally, percentage reduction in tumour area, per treatment, was stratified by tumour location/zone and analysed by ANOVA.

**RESULTS**

Thirty six tumours in 27 eyes of 21 patients were evaluated for response following 1–3 cycles of carboplatin. Table 1 summarises the patient demographics.

At baseline, 16 tumours measured 0–4 dd (44%), 19 tumours measured 4–10 dd (53%), and one tumour was more than 10 dd (3%; fig 1). Following initial carboplatin treatment (mean follow up 22.0 days; 12–41), 34/36 tumours (94.4%) showed a response to treatment and 2/36 (5.6%) were stable. No tumours progressed. The mean reduction in area was 37.1% (median 37.0%; 4.0%–76.7%) and the mean reduction in largest basal diameter was 21.3% (median 21.0%; –7.9%–52.5%). Tumour response following initial carboplatin treatment is stratified in figure 2.

Twenty of the original 36 tumours received a second cycle of carboplatin (mean follow up 26.1 days; range 20–35): 15

---

**Figure 1** Initial size of tumour at the time of first treatment with systemic carboplatin. The largest basal diameter for each tumour (1 disc diameter = 1.5 mm) was measured using RET-CAM imaging.

**Table 1** Patient and tumour demographics.

<table>
<thead>
<tr>
<th>Variable</th>
<th>No (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>12 (57%)</td>
</tr>
<tr>
<td>Female</td>
<td>9 (43%)</td>
</tr>
<tr>
<td>Mean age at diagnosis (months) (range)</td>
<td>9 (0.75–28.5)</td>
</tr>
<tr>
<td>Disease involvement*</td>
<td>4</td>
</tr>
<tr>
<td>Bilateral</td>
<td>15 (71%)</td>
</tr>
<tr>
<td>Unilateral</td>
<td>6 (29%)</td>
</tr>
<tr>
<td>Tumour location</td>
<td></td>
</tr>
<tr>
<td>Macular</td>
<td>8 (22%)</td>
</tr>
<tr>
<td>Macular-equator</td>
<td>22 (61%)</td>
</tr>
<tr>
<td>Equator-ora serrata</td>
<td>6 (17%)</td>
</tr>
</tbody>
</table>

*At diagnosis and follow up (mean follow up = months).

---

**Figure 2** Percentage reduction in tumour area after one initial treatment with systemic carboplatin, stratified.
Previous studies have evaluated the response of intraocular retinoblastoma to chemoreduction using a variety of outcome variables and methodologies. The purpose of this study is to add to the existing literature measurements of tumour response after carboplatin chemotherapy. We chose to record the morphology of tumours in two dimensions before and after therapy, and felt this to be an accurate representation of response. Ocular and patient survival, and/or effectiveness of additional treatments for retinoblastoma were not assessed in this study.

Shields et al measured change in size of 54 tumours in 31 eyes following a 2 month regimen (two cycles) of triple agent chemotherapy (VEC). A 29% mean reduction in basal diameter and 40% mean reduction in thickness was reported after one cycle. A second cycle yielded a 35% cumulative reduction in basal diameter and 49% in thickness. Each tumour was measured via echography and estimates by indirect ophthalmoscopy. Digital imaging was not used in reporting the data. The response rate to treatment was 100%: approximately 50% of the tumours classified achieved a complete response after 2 months and the remaining 50% achieved a partial response. No progressive disease was seen. In their analysis, the authors noted that larger tumours demonstrated a more dramatic response to treatment, but the percentage shrinkage was nearly identical between tumours >8 mm thick versus tumours <8 mm thick. Furthermore, they reported that in some patients, reduction in tumour size correlated with the location of the intraocular tumour: reduction correlated with increased distance of the tumour from the optic disc and foveola.

Sussman et al utilised RET-CAM imaging and echography to evaluate the effects of chemotherapy (VEC plus or minus cyclosporin) on RE group IV–V retinoblastomas. Their study did not purport to isolate the effects of systemic chemotherapy alone—patients received concurrent transpupillary diode laser and/or cryotherapy. The study objective was to compare the time course and extent of tumour reduction associated with this treatment regimen versus EBR in treating advanced intraocular retinoblastoma. Only the largest tumour in an eye was evaluated. The authors concluded that reduction in tumour volume was greatest in the first 2 months of therapy (68% reduction from baseline after 1 month) and disappeared by 12 months.

Finally, Demirci et al studied 10 eyes with intraocular retinoblastoma that had been enucleated after receiving an average of four cycles of VEC. Nine of the eyes were RE groups IV–V, and all 10 eyes had been enucleated for tumour recurrence as subretinal seeds and/or vitreous seeds (seven) or for vitreous haemorrhage (three). A 24% mean reduction of basal diameter and 34% in thickness of the main tumour in each eye was observed from pretreatment baseline to the time of enucleation.

Of the 36 tumours we measured following exposure to carboplatin (1–3 cycles), 94% responded. The remaining tumours were stable. One tumour progressed following the third cycle of carboplatin. These results are comparable with reported tumour regression following chemothermotherapy (CTT): whereby 96% of tumours responded after 1–6 cycles. CTT consists of transpupillary thermotherapy (TTT) delivered to a tumour shortly after IV administration of carboplatin (plus or minus etoposide), with repeated TTT 8 days later.

One cycle of carboplatin alone produced a 37.1% mean reduction in tumour area (Fig 4A and 4B). We found a continued reduction (17.8%) in area after a second cycle. All tumours subject to two cycles of carboplatin showed substantial cumulative regression (mean reduction in area 55.1%). When we looked at tumour response in terms of percentage reduction of the largest basal diameter, as other

Figure 4 shows RET-CAM images of two representative solitary tumours, each before and after treatment with primary carboplatin.
studies have done, we found a 21.3% mean decrease after one cycle of carboplatin. Two and three cycles of chemotherapy resulted in a cumulative reduction in largest basal diameter of 33.6% and 38.8%, respectively. While variations in methodology limit comparison between individual studies, our results suggest that tumour response to treatment with a single agent (carboplatin) is comparable to that achieved in studies evaluating treatment with multiple agents.

Tumour response appeared to level off after two cycles of carboplatin. It is possible that maximal benefit of systemic chemotherapy is achieved during the first two cycles of treatment and that the residual mass represents treated tumour. It is also possible that our study selected for resistant tumours by focally treating tumours that responded more favourably to systemic carboplatin. Regardless, our observation is consistent with tumour reduction following EBR; it too appears to plateau, although the time to the plateau following EBR appears to be greater.15 Gombos et al, in an attempt to identify factors predictive of outcome, described tumour associated features of retinoblastomas successfully responding to triple agent chemotherapy (VEC). Their results suggested that small tumours (<2 mm in basal diameter) were potentially less responsive to systemic chemotherapy.16 Furthermore, tumours in the macular region were more likely to be managed by systemic chemotherapy alone than tumours in the periphery; perhaps because disproportionate choroidal blood flow to the macular region facilitated greater drug delivery to centrally located tumours. Our study classified tumours on the basis of largest basal diameter in disc diameters (0–4 dd, 4–10 dd, and >10 dd); size ranges reflecting the dimensions used for RE classification. Our analysis did not reveal a significant correlation between the location of a given tumour and its percentage reduction in tumour area than smaller tumours for each treatment. Our analysis also did not reveal a correlation between the location of a given tumour and its percentage reduction in area following treatment with carboplatin. Given the information from previous studies by others, it is likely that our study was underpowered to detect differences in the percentage reduction across location.

Our results demonstrate quantifiable tumour chemoreduction following treatment with carboplatin. It appears comparable to the reported tumour response data following treatment with multi-agent chemotherapy; in terms of percentage reduction in largest basal diameter, percentage reduction in area, response rate, and early timing of maximum response. Our data suggest that, perhaps for some tumours, there is not a direct relation between the additional exposure to multiple chemotherapeutic agents and additional tumour reduction. We did not assess response to carboplatin treatment in terms of eye survival and/or eye event free survival, choosing not to introduce such variables as which focal technique is applied following chemoreduction, how often and how long it is applied, and the actual techniques used in applying the focal technique (which vary from centre to centre). Knowing that carboplatin alone will not cure the tumours despite a good initial response, complete analysis of these variables is necessary in order to (1) evaluate the overall success of a chemoreduction and focal therapy strategy for curing intraocular retinoblastoma, and (2) fully disclose to patients information regarding the risks and benefits of treatment choices.

Authors’ affiliations
D H Abramson, K L Beaverston, T C Lee, I S Rollins, Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
D H Abramson, S D Lawrence, T C Lee, Department of Ophthalmology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA
K L Beaverston, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
D H Abramson, I J Dunkel, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Supported in part by the Fund for Ophthalmic Knowledge, New York, NY, USA.

Competing interests: none declared

REFERENCES